• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

射血分数降低和保留的心衰患者的成本比较:失代偿性心力衰竭入院患者的分析。

Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions.

机构信息

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, Boston, MA, United States.

Division of Cardiology, Cardiovascular Center, Tufts Medical Center, Boston, MA, United States.

出版信息

Int J Cardiol. 2018 Jun 15;261:103-108. doi: 10.1016/j.ijcard.2018.03.024.

DOI:10.1016/j.ijcard.2018.03.024
PMID:29657034
Abstract

BACKGROUND

Heart failure (HF) is the leading cause of inpatient admissions in the US for adults aged over 65 years and accounts for more than $17 billion in Medicare expenditures annually. There are limited published data on factors influencing expenditure and the relationship between cost and hospital length of stay. We sought to describe institutional costs of HF hospitalization, as well as demographic and clinical predictors of higher hospitalization costs in an academic hospital setting.

METHODS AND RESULTS

Demographic and clinical information was collected retrospectively for 564 unique consecutive patients with a decompensated HF admission during 2010-2013. Forty-six percent had a baseline LVEF >40%, categorized as HF with preserved ejection fraction (HFpEF). Forty-three percent were female and the mean age was 71 years. Patients with reduced ejection fraction (HFrEF) were predominantly male, younger and had a lower burden of baseline comorbidities than HFpEF patients. Length of stay was longer for HFrEF (median 4 days) than HFpEF (median 3 days, p = 0.01). Mean total hospitalization cost was $9521. Mean costs trended higher for HFrEF patients than for HFpEF patients ($10,286 versus $8858, p = 0.07). Room and board contributed more than half of all costs.

CONCLUSIONS

In this single-center study, we observed a trend towards higher HF hospitalization costs for patients with HFrEF, compared to HFpEF, even though patients with HFpEF are older and had more comorbid conditions. Costs were largely driven by length of stay, with higher heart rate at admission, lower systolic blood pressure, and higher creatinine associated with higher inpatient costs.

摘要

背景

心力衰竭(HF)是美国 65 岁以上成年人住院的主要原因,每年医疗保险支出超过 170 亿美元。关于影响支出的因素以及成本与住院时间之间关系的已发表数据有限。我们旨在描述心力衰竭住院的机构成本,以及在学术医院环境中影响更高住院费用的人口统计学和临床预测因素。

方法和结果

回顾性收集了 2010 年至 2013 年期间 564 例失代偿性 HF 入院的独特连续患者的人口统计学和临床信息。46%的患者基线 LVEF>40%,归类为射血分数保留的心力衰竭(HFpEF)。43%为女性,平均年龄为 71 岁。射血分数降低的心力衰竭(HFrEF)患者主要为男性,年龄较小,基线合并症负担低于 HFpEF 患者。HFrEF 患者的住院时间较长(中位数 4 天)比 HFpEF 患者(中位数 3 天,p=0.01)。平均总住院费用为 9521 美元。HFrEF 患者的平均费用高于 HFpEF 患者($10286 比$8858,p=0.07)。房间和董事会贡献了超过一半的所有费用。

结论

在这项单中心研究中,我们观察到与 HFpEF 相比,HFrEF 患者的 HF 住院费用呈上升趋势,尽管 HFpEF 患者年龄更大,合并症更多。成本主要由住院时间驱动,入院时心率较高、收缩压较低、肌酐较高与住院费用较高相关。

相似文献

1
Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions.射血分数降低和保留的心衰患者的成本比较:失代偿性心力衰竭入院患者的分析。
Int J Cardiol. 2018 Jun 15;261:103-108. doi: 10.1016/j.ijcard.2018.03.024.
2
National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure.心力衰竭住院期间心房颤动负担的国家趋势。
J Am Heart Assoc. 2021 Jun;10(11):e019412. doi: 10.1161/JAHA.120.019412. Epub 2021 May 20.
3
A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program.射血分数降低的心力衰竭(HFrEF)与射血分数保留的心力衰竭(HFpEF)在住院及纳入疾病管理项目后的第一年的临床工作量和成本比较。
Int J Cardiol. 2017 Apr 1;232:330-335. doi: 10.1016/j.ijcard.2016.12.057. Epub 2016 Dec 23.
4
Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.比较城市队列中射血分数保留型心力衰竭与射血分数降低型心力衰竭患者的特征和结局。
Am J Cardiol. 2014 Feb 15;113(4):691-6. doi: 10.1016/j.amjcard.2013.11.014. Epub 2013 Nov 23.
5
Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission.急性心力衰竭入院后出院的心力衰竭患者的两年结局及费用
Int J Cardiol. 2020 May 15;307:109-113. doi: 10.1016/j.ijcard.2019.10.033. Epub 2019 Oct 24.
6
Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.左心室射血分数中等范围的急性心力衰竭:临床特征、住院治疗及短期预后
Clin Res Cardiol. 2017 May;106(5):359-368. doi: 10.1007/s00392-016-1063-0. Epub 2016 Dec 20.
7
Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans.商业保险和补充医疗保险计划下真实世界心力衰竭人群的当代经济负担。
Clin Cardiol. 2021 May;44(5):646-655. doi: 10.1002/clc.23585. Epub 2021 Mar 11.
8
Clinical characteristics and prognosis of patients admitted for heart failure: A 5-year retrospective study of African patients.因心力衰竭入院患者的临床特征与预后:对非洲患者的一项5年回顾性研究
Int J Cardiol. 2017 Jul 1;238:128-135. doi: 10.1016/j.ijcard.2017.03.014. Epub 2017 Mar 6.
9
Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction.射血分数改善或恢复的成年心力衰竭门诊患者的特征和结局。
JAMA Cardiol. 2016 Aug 1;1(5):510-8. doi: 10.1001/jamacardio.2016.1325.
10
Trends in Heart Failure Hospitalizations in the US from 2008 to 2018.2008 年至 2018 年美国心力衰竭住院治疗趋势。
J Card Fail. 2022 Feb;28(2):171-180. doi: 10.1016/j.cardfail.2021.08.020. Epub 2021 Sep 15.

引用本文的文献

1
Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.肝硬化与其他常见慢性病的成本比较:一项基于大型 national 保险数据库的纵向研究。 注:原文中“national”前似乎少了个限定词,比如“national health”(国民健康)等,不然单独的“national”在这里语义不太完整。
Hepatology. 2025 Jan 6. doi: 10.1097/HEP.0000000000001206.
2
Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.恩格列净在射血分数轻度降低和保留的心衰患者中的成本效益分析。
ESC Heart Fail. 2024 Feb;11(1):261-270. doi: 10.1002/ehf2.14565. Epub 2023 Nov 15.
3
Differentiating Characteristics and Responses to Treatment of New-Onset Heart Failure With Preserved and Reduced Ejection Fraction in Ambulatory Patients.
门诊患者射血分数保留和降低的新发心力衰竭的鉴别特征及治疗反应
Cardiol Res. 2023 Jun;14(3):201-210. doi: 10.14740/cr1483. Epub 2023 May 26.
4
Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study.马来西亚慢性心力衰竭管理的成本分析:一项多中心回顾性研究。
Front Cardiovasc Med. 2022 Nov 2;9:971592. doi: 10.3389/fcvm.2022.971592. eCollection 2022.
5
Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting.在全国范围内,射血分数谱中心力衰竭的负担持续存在。
J Am Heart Assoc. 2022 Nov 15;11(22):e026708. doi: 10.1161/JAHA.122.026708. Epub 2022 Nov 3.
6
Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.西班牙射血分数保留、轻度降低和降低的心衰患者的医疗资源利用和成本。
BMC Health Serv Res. 2022 Oct 8;22(1):1241. doi: 10.1186/s12913-022-08614-x.
7
Burden of hospitalization for heart failure in the United States: a systematic literature review.美国心力衰竭住院负担:系统文献回顾。
J Manag Care Spec Pharm. 2022 Feb;28(2):157-167. doi: 10.18553/jmcp.2022.28.2.157.
8
Relationship Between Heart Failure Hospitalization Costs and Left Ventricular Ejection Fraction in an Advanced Aging Society.老龄化社会中的心衰住院费用与左心室射血分数之间的关系
Circ Rep. 2021 Nov 17;4(1):48-58. doi: 10.1253/circrep.CR-21-0134. eCollection 2022 Jan 7.
9
Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review.射血分数保留的心力衰竭(HFpEF)相关的住院费用:一项系统评价。
Heart Fail Rev. 2022 Mar;27(2):559-572. doi: 10.1007/s10741-021-10097-7. Epub 2021 Mar 25.
10
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).美国与心力衰竭相关的医疗费用的系统评价(2014-2020 年)。
Pharmacoeconomics. 2020 Nov;38(11):1219-1236. doi: 10.1007/s40273-020-00952-0.